A200 VEDOLIZUMAB IS AN EFFECTIVE TREATMENT OPTION FOR NON INFLAMMATORY BOWEL DISEASE RELATED ENTEROPATHY
نویسندگان
چکیده
منابع مشابه
Vedolizumab for the treatment of inflammatory bowel disease.
The causes of inflammatory bowel diseases, such as ulcerative colitis (UC) and Crohn's disease (CD), remain to be elucidated. However, characteristic inflammation of the gastrointestinal mucosa is caused by infiltration of T lymphocytes into the submucosal layer. Inhibiting this immune response is a promising therapeutic target. Integrins expressed on the cell surface mediate gut homing of T ly...
متن کاملDesigning biologic selectivity for inflammatory bowel disease – role of vedolizumab
Crohn's disease and ulcerative colitis are two chronic inflammatory bowel conditions. Current approved biologic therapies are limited to blocking tumor necrosis factor alpha. Unfortunately, some patients are primary nonresponders, experiencing a loss of response, intolerance, or side effects. This defines an unmet need for novel therapeutic strategies. The rapid recruitment and inappropriate re...
متن کاملIntestinal permeability, non-steroidal anti-inflammatory drug enteropathy and inflammatory bowel disease: an overview.
There is recent renewed interest in the role of the intestine in the pathogenesis of the various arthritides'7. In general, it is postulated that an intestinal microbial constituent or product is absorbed by the intestinal mucosa eliciting an immunological response and tissue damage by simple or induced molecular mimicry"'. The difference between the two mechanisms can best be shown by consider...
متن کاملan overview on inflammatory bowel disease treatment
inflammatory bowel disease (ibd) is a chronic relapsing, idiopathic disorder of the gastrointestinal tract of an unknown etiology. ulcerative colitis (uc) and crohn's disease (cd) have become important health problems.â current medical therapy of ibd has advanced dramatically with the introduction of new biologic therapies in addition to the optimization of conventional therapies that include ...
متن کاملPRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases
Vedolizumab is an anti-inflammatory monoclonal antibody that exclusively targets the α4β7 integrin. We aimed to systematically review the efficacy and safety of vedolizumab for patients with inflammatory bowel diseases (IBDs). PubMed, EMBASE, and the Cochrane Library were searched up to May 2014. Randomized controlled trials examining the efficacy or safety of vedolizumab in patients with IBDs ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the Canadian Association of Gastroenterology
سال: 2021
ISSN: 2515-2084,2515-2092
DOI: 10.1093/jcag/gwab002.198